FOCUSED. COMMITTED.
DRIVEN.

We are working tirelessly to meet the needs of our target adult consumers by leveraging our team and state-of-the-art facility to accelerate speed to market and produce premium products at a low operating cost.


READ MORE

FOCUSED.
COMMITTED.
DRIVEN.


We are working tirelessly to meet needs of our target adult consumers by leveraging our team and state-of-the-art facility to accelerate speed to market and produce premium products at a low operating cost.

SHOW MORE

Cannara Biotech Inc. Appoints Donald Olds to Board of Directors
Cannara Biotech Inc. today announced the appointment of Donald Olds as a Director on the Company's board of directors.

Cannara Biotech Inc. Reports Q3 2020 Financial Results
Cannara Biotech Inc. today announced financial results for the three and nine-month periods ended May 31, 2020. Unless otherwise noted, all dollar amounts are expressed in Canadian dollars.

Cannara Completes Acquisition of Global shopCBD.com
Cannara Biotech Inc. ("Cannara") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB) announced today it has closed on its previously announced offer to acquire all of the issued and outstanding shares of Global shopCBD.com Inc.

Cannara enters LOI with SQDC for Entire First Year Production
Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB) announced today it has finalized a non-binding Letter of Intent (LOI) with the Société québécoise du cannabis (the "SQDC").

Cannara Proposes Agreement to Acquire Global shopCBD.com
Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB), an emerging vertically integrated cannabis company focused on indoor cultivation, processing and sale of premium dried cannabis and cannabis derivative products,

Cannara Biotech Inc. appoints Mary Durocher as New Board Director
Cannara Biotech Inc. today announced the appointment of Mary Durocher as a Director on Cannara's Board, effective immediately.

Cannara Harvests First Crop on 420
300 kgs of Carefully Crafted Premium Indoor Cannabis Marks Pivotal Milestone

Cannara Biotech Inc. Reports Q2 2020 Financial Results
Company well-financed with ample resources to reach commercial milestones in H2 2020

Cannara Insiders Form Buying Group to Fully Acquire FSD/FV Pharma's Position in Cannara
Cannara Biotech Inc. today announced a buying group which includes Javaa Private Equity Inc. ("Javaa") has collectively acquired a total of 85,003,250 common shares from FSD/FV Pharma Inc.

Cannara Biotech's Farnham Facility Receives Cultivation Licence
Today announced the receipt of its cultivation licence from Health Canada for Phase 1 of its purpose-built Farnham Facility.

Cannara Biotech Reports Q1 2020 Financial Results
Today announced financial results for the three-month period ended November 30, 2019.

Cannara Biotech Reports Q4 and Year-End 2019 Financial Results
Today announced financial results for the three month period and year ended August 31, 2019.

Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce
Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce.

Cannara Biotech Submits Site Evidence Package to Health Canada for its Quebec Facility
Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB), an emerging vertically integrated cannabis company focused on indoor cultivation and sale of premium cannabis and cannabis-infused products, announced it has submitted to Health Canada.

Cannara Announces Appointment of New Chief Operating Officer
Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried.

Cannara Biotech Inc. Reports Q3 2019 Results
Cannara Biotech ("Cannara" or the "Company") (CSE: LOVE) (FRA: 8CB) (OTCQB: LOVFF), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried premium cannabis and cannabis-infused products.

Cannara Biotech Announces Non-Brokered Private Placement of 12,000,000 Common Shares
Cannara Biotech Inc. (the "Corporation" or "Cannara") (CSE: LOVE, FRA: 8CB, OTCMKTS:LOVFF), an emerging vertically integrated cannabis company focused on cultivation, and cannabis-infused products, is pleased to announce that it has raised $2,160,000 by way of non- brokered…

President’s Message
It has been a highly productive first year for Cannara and I want to commend the entire team on delivering a number of impactful milestones in our first year within this exciting and continually evolving cannabis sector…

Cannara Biotech Appoints Dr. Sara May to its Board of Directors
Cannara Biotech ("Cannara" or the "Company") (CSE: LOVE, FRA: 8CB, OTCMKTS: CNBTF), an emerging vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced the appointment of Dr. Sara May, PhD. to the…

Cannara Biotech Commences Trading on the OTCQB Market in the United States
Cannara Biotech ("Cannara" or the "Company") (CSE: LOVE, FRA: 8CB), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried cannabis and cannabis-infused…

Cannara Biotech Reports Q2 2019 Results
Cannara Biotech ("Cannara" or the "Company") (CSE: LOVE) (FRA: 8CB), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried cannabis and cannabis-infused products to the Canadian and international markets, today…

Cannara Biotech Announces Expansion of Phase 1 Build-Out and Board of Directors Update
Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE) (FRA: 8CB), a vertically integrated cannabis company in the making focused on cultivation and cannabis- infused products, today announced an expansion of the Phase 1 build-out of Cannara’s facility from 130,000 to 170,000 square feet. As a result, the license application at Cannara’s Farnham, in process with…

Cannara Biotech Shares to Begin Trading on the Frankfurt Exchange
Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (CSE: LOVE) (FRA: 8CB), a vertically integrated cannabis company focused on cultivation and cannabis- infused products, today announced its…

Cannara Biotech Enters Cannabinoid-Infused Beverage Product Category Partners with a Leading Quebec Microbrewery
Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (CSE: LOVE), a Montreal-based company that is building a vertically integrated cannabis company focused on cultivation and cannabis…

Cannara Biotech Reports First Quarter Results
Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE), is building a vertically integrated Cannabis company focused on cannabis derivative products, today announced its financial results for the three-month period ended November 30, 2018…

Cannara Biotech to Enter the U.S. Hemp-CBD Market. Launching an Online E-Commerce Platform – ShopCBD.com
Cannara Biotech Inc. ("Cannara" or the "Company") (CSE: LOVE), is building a vertically integrated Cannabis company focused on cannabis-infused products, today announced it is entering the U.S. Hemp-CBD market, through a subsidiary, with an online e-commerce platform called shopCBD.com…

Cannara Biotech to Commence Trading on CSE Monday January 14 Under Ticker Symbol "LOVE"
Cannara Biotech Inc. ("Cannara" or the "Company"), a vertically integrated Cannabis company focused on cannabis derivative products, is pleased to announce that its common shares will begin trading on Monday, January 14, 2019 on the Canadian Securities Exchange (CSE) under the symbol "LOVE."

Financial Statements For the three and nine-month periods
CANNARA BIOTECH INC. Condensed Interim Consolidated Financial Statements For the three and nine-month periods ended May 31, 2020 and 2019

MDA Q3 2020
CANNARA BIOTECH INC. MANAGEMENT DISCUSSION AND ANALYSIS For the three and nine-month periods ended May 31, 2020 and 2019

MD&A Q2 2020
MANAGEMENT DISCUSSION AND ANALYSIS For the three and
six-month periods ended February 29, 2020 and February 28, 2019

Financial Statements Q2 2020
Condensed Interim Consolidated Financial Statements
For the three and six-month periods ended February 29, 2020 and February 28, 2019 (Unaudited)

Financial Statements Q1 2019
Condensed Interim Consolidated Financial Statements.
Three-month periods ended November 30, 2019 and 2018 (Unaudited).

MD&A Q1 2019
MANAGEMENT DISCUSSION AND ANALYSIS.
For the three-month periods ended November 30, 2019 and 2018.

MD&A Q4 2019
MANAGEMENT DISCUSSION AND ANALYSIS.
Three and six month periods ended August 31, 2019.

Q4 and Year-End Financial Statements 2019
Audited Consolidated Financial Statements of Year-ended Aug. 31, 2019 and 191-day period ended Aug. 31, 2019.

Financial Statements Q3 2019
Condensed Interim Consolidated Financial Statements.
Three and six month periods ended May 31, 2019.

MD&A Q3 2019
MANAGEMENT DISCUSSION AND ANALYSIS.
Three and six month periods ended May 31, 2019.

Financial Statements Q2 2019
Condensed Interim Consolidated Financial Statements.
Three and six month periods ended February 28, 2019.

MD&A Q2 2019
MANAGEMENT DISCUSSION AND ANALYSIS.
Three and six month period ended February 28, 2019.